Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 15/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | EED | O75530 | 1/20 | 0.55 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.55 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.55 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19503268 | 0.93 | EZH2 (0.69) | EZH2HDAC6HDAC1EEDRBBP4 | |
| SCHEMBL19503236 | 0.91 | EZH2 (0.84) | EZH2HDAC6HDAC1EEDRBBP4 | |
| SCHEMBL30687988 | 0.84 | EZH2 (0.81) | EZH2HDAC6HDAC1 | |
| SCHEMBL13280847 | 0.83 | EZH2 (1.00) | EZH2HDAC6HDAC1EEDRBBP4 | |
| SCHEMBL19503505 | 0.83 | EZH2 (0.81) | EZH2HDAC6HDAC1EEDRBBP4 | |
| SCHEMBL17732395 | 0.83 | EZH2 (0.89) | EZH2HDAC6HDAC1 | |
| SCHEMBL13276839 | 0.82 | EZH2 (1.00) | EZH2HDAC6HDAC1 | |
| SCHEMBL30878122 | 0.82 | EZH2 (1.00) | EZH2HDAC6HDAC1 | |
| SCHEMBL19503337 | 0.82 | EZH2 (0.55) | EZH2HDAC6HDAC1EEDRBBP4 | |
| SCHEMBL13277416 | 0.82 | EZH2 (1.00) | EZH2HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633371-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20200039968-A9 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20190135796-A1 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| WO-2017184999-A1 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135796-A1 | EZH2 INHIBITORS AND USES THEREOF | EZH2, EZH1, BMI1 | EZH2 1/4885HDAC6 109/4885HDAC1 20/4885 |
| US-20200039968-A9 | EZH2 INHIBITORS AND USES THEREOF | EZH2, EZH1, BMI1 | EZH2 1/4885HDAC6 109/4885HDAC1 20/4885 |
| US-10633371-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | EZH2 1/4885HDAC6 109/4885HDAC1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.